Julie Yoo

1. Key Themes

Transparency and Trust as the Core Product, Not Technology

Cuban frames Cost Plus Drugs as a trust business, not a pharmacy or tech business. Julie Yoo notes the company's mere existence has forced incumbents to change in ways decades of policy never did. Cuban says the moat is trust earned through radical transparency, with no marketing spend.

Cuban: "Trust is still our primary product." 00:23:20 He explains: "We don't spend any money on marketing or advertising... people are going to tell others how much money they saved and then they're going to trust us. And that's the one thing missing in all of healthcare economics, trust." 00:23:20

Yoo on the second-order effect: "just merely by the presence of Cost Plus Drugs... you've actually forced change in the incumbents that otherwise, even with policy... never changed over the course of many, many decades." 00:00:05

AI's Highest-Leverage Use Today: Contract Review Before You Sign

The most actionable idea in the episode is also the simplest. Cuban argues employers can capture enormous savings by running contracts through an LLM before signing, and that the system could "collapse" if employers collectively did this.

Cuban: "I'm running my existing contract through AI and I'm using a prompt that asks a single question: Where are they fucking me over and what should I do about it? And within 30 seconds, you're going to see bam, bam, bam." 00:17:34 He adds: "if the employers representing 67%, the 160 million-plus Americans actually did one thing... ran their contracts through AI before they signed them and negotiated from that, the entire system for the big BUKAs and big PBMs and all their subsidiaries would collapse. The cost of healthcare in this country would drop like a rock." 00:17:34

Contractual Terrorism: Why AI Can't Fix a Broken Contract After Signing

Cuban's sharpest distinction is between AI as a pre-signing shield and AI as a post-signing fix. Contract complexity is a weapon, and once signed, no tool can save you.

Cuban: "the city of Dallas on their PBM contract... 1,335 pages. There's no group of humans with enough coffee on the planet to be able to catch everything they try to squeeze by... once you sign that contract with terms you don't fully understand and conditions you don't fully you can't even protect yourself against, they win. There's no AI in the planet that can protect you." 00:14:34

Vertical Integration and Opacity: The Real Structural Problem

Cuban describes how the big carriers use scale, subsidiaries, and data silos to extract value invisibly, especially on the medical side, which dwarfs pharmacy.

Cuban: "UnitedHealth, 3,000-plus subsidiaries, $150 billion in intercompany transfers annually. That would make them number 14 in GDP in the United States among states." 00:00:15 On self-insured employers: "the price that... the self-insured employer pays, rarely matches the amount that was charged or that amount that was paid to the hospital. So there's a spread pricing there... the employers have no access to it. And in many cases, they don't even have access to their own claims." 00:12:38

Direct Contracting as the Wedge, With Open-Source Contracts

Cuban's direct-to-hospital model trades simplicity (no pre-auths, no denials, on-time payment, assuming patient credit risk) for lower prices and the right to publish the contract publicly.

Cuban: "I'm going to trust the doctor... I'm going to pay the price that we contract for on time. I'm going to take responsibility for the patient out-of-pocket... And in exchange for all that, I want two things. I want a better price... and I want the ability to take the contract we sign... and publish it on costpluswellness.com, so it can act as a open source for all of these contracts." 00:04:18

Vertical Integration of Manufacturing: Pods, Robotics, and the N-of-1 Future

Cost Plus is building modular, AI/robotics-driven manufacturing that shrinks a football-field facility into 5,000 square feet and then into a tractor-trailer "pod," sold at about $20M each.

Cuban: "we were able to use AI and to use robotics to shrink what would have been a football field or more into 5,000 square feet... we can make a six-month supply, turn the line, and then go to the next drug." 00:04:18 And on scale: "You give me... a 1,000 pods to sell at $20 million each, we're going to be doing really, really, really good. And it'll completely change healthcare." 00:23:20

Personalized Medicine Approaching Zero Marginal Cost

Cuban predicts the cost of designing a drug personalized to your DNA approaches zero as algorithms improve, and that frontier labs should bundle it into subscriptions.

Cuban: "The cost of designing a drug personalized to you after reviewing your DNA and knowing everything that it knows will start approaching zero as the capabilities of models go up." 00:36:45 "it's the algorithms that are going to change everything and make them more efficient... it will be part of a normal subscription, because there's no reason it shouldn't be." 00:36:45

The Doctor's Role Shifts to Physician-Scientist

Yoo and Cuban converge on doctors becoming collectors of novel individual data rather than rote task-performers. Cuban insists humans remain essential due to model latency and the need for human senses.

Yoo: "what if like the paradigm moves towards physicians are actually like more physician scientists... at the tip of the spear of collecting novel data, generating novel insights about how people are reacting to things." 00:44:13 Cuban: "Novel data equals person." 00:44:42

Agent-Driven Economy Needs New Infrastructure

Cuban notes agents can't see social posts, ads, or transcripts easily, implying a need to rebuild how commerce and content are communicated to agents.

Cuban: "agents don't see social media posts... They can't, you know, watch ads or see ads. And so, if we're moving to an agent driven economy for individuals, there's going to have to be a lot of changes that occur and how we communicate commerce to those agents." 00:30:43

AI Fluency in the C-Suite Is the Binding Constraint

Cuban stresses that executive understanding, not model capability, is the bottleneck. His cookie example shows how many leaders don't know what to ask an LLM.

Cuban: "I'm going to ask ChatGPT to create a competitor that is more GLP-1 friendly and will be priced lower, and I want a full bill of materials, I want sources, everything of manufacturing... in about 3 minutes... he was like, 'Oh, shit.'" 00:27:48

2. Contrarian Perspectives

AI Is a Great Equalizer, So It Won't Dramatically Change Payer-Provider Dynamics

Against the prevailing narrative that AI will transform claims and prior auth, Cuban argues the bot war nets out because both sides have the same tools.

Cuban: "AI is a great equalizer. Your AI, my AI... we're going to battle each other out, and you might win a couple innings, I'll win a couple innings, but they're going to net out at some level. So, I don't see dramatic change in the long term." 00:17:34

The Big Carriers Will Struggle to Become AI-Native Because of Their Own Acquisitions

Most assume scale advantages compound with AI. Cuban says siloed data from 3,000 subsidiaries is a liability.

Cuban: "the BUKAs have a big problem in my opinion because they grew through acquisitions. We mentioned these 3,000 subsidiaries. That's a lot of siloed data... it's going to be hard for them to... become AI-native companies on the BUKA side. And I think over the long term, they're going to be challenged." 00:17:34

You Don't Need Legislation to Fix Employer Healthcare Costs; You Need a Healthcare CEO/CFO

While Cuban supports policy changes, he says employers are the unlock and should hire someone solely accountable for healthcare contracts.

Cuban: "I'm like, 'No. You need to be smart and do your job and bring in somebody that I call a healthcare CEO or CFO whose only job is to manage the contracts and everything associated with it, and you will find that your healthcare costs will go down.'" 00:17:34

Healthcare Will Stay a Large Share of GDP, and That's Fine

Contrary to the "bend the cost curve" orthodoxy, Cuban expects healthcare to remain roughly a fifth of GDP, justified by productivity gains from a healthier population.

Cuban: "the value you get out of the people will increase, cuz they'll be healthier... there's a difference when it's sick care... versus when it's keeping people healthy and they're more productive, and there's less downtime." 00:47:59

Information Wants to Be Free Doesn't Hold: IP Owners Will Gate Medical AI

Responding to Erik Torenberg's Aaron Swartz reference, Cuban predicts a world of paywalled models and protected IP.

Cuban: "The information might may want to be free, but the person who owns the IP feels differently... you might say, 'No, you have to come to my model and you have to pay me $9,999 every access.'" 00:40:43

3. Companies Identified

Cost Plus Drugs

Mark Cuban's transparent-pricing pharmacy launched January 19th, 2022 with 111 generics, now about 4,000 SKUs. Mentioned as the central case study of disruption through transparency. Cuban: "we launched costplusdrugs.com January 19th of 2022. 111 medications, purely generic... So now... we have 4,000 SKUs give or take, and our business every week is up and to the right. So, our biggest challenge is just keeping up with it." 00:04:18

Team Cuban Card

Discount card network letting customers pick up Cost Plus drugs at about 17,000 affiliated pharmacies, paying independents a $12 fill fee. Cuban: "we pay our affiliate pharmacies $12 fill fee... on the more expensive drugs, the specialty generics, the biosimilars, we're actually much cheaper." 00:04:18

Cost Plus Marketplace

B2B sales of sterile injectables to hospitals and clinics at cost-plus 10 or 12. Cuban: "we sell them at a cost-plus 10 or cost-plus 12 to clinics, hospitals, providers... we literally can save hospitals millions of dollars a year. But, our biggest challenge there is we convinced the CEOs, but we can't always convince the purchasing people." 00:04:18

Cost Plus Wellness

Platform for publishing open-source direct contracts between employers and providers. Cuban: "publish it on costpluswellness.com, so it can act as a open source for all of these contracts." 00:04:18

Cost Plus Drugs Manufacturing (Dallas Facility and Pods)

Robotics/AI manufacturing producing FDA short-supply drugs and ASO drugs, with modular $20M "pods" for any location. Cuban: "The government was our first customer. We've shipped the first one here recently. We just got an order for a second and they've told us there's more behind that." 00:04:18

Sidecar (Sidecar Health)

Mentioned as an example of a startup competing with carriers on plan design. Cuban: "What Sidecar is doing and so many others are doing is really smart. But they're having problems because... those BUKAs have so many subsidiaries, they fuck with you somewhere and you don't even realize it." 00:15:46

Epic Systems

Dominant EHR vendor partnering with Cost Plus to expose pricing at point of prescribing. Cuban: "offering pricing, particularly pharmaceutical pricing, at the point of script where the doctor is there offering them different options is a good start." 00:46:37

Amazon

Named alongside Epic in the point-of-prescription pricing announcement. Cuban: "Yeah, exactly, exactly, with Epic and Amazon, etc." 00:47:03

OpenEvidence

Clinical AI tool Cuban says doctors will be trained to use. Cuban: "They'll have to learn how to use OpenEvidence or whatever else is available out there to... extract information." 00:40:43

23andMe

Used as a cost benchmark for DNA analysis in the personalized medicine thesis. Cuban: "How expensive is 23andMe? You pay $99 or less now to get your DNA looked at." 00:36:45

Grok, OpenAI/ChatGPT, Anthropic/Claude, Gemini

Cuban describes using all of them as agents for contract analysis and open records requests. Cuban: "I use GrokBot... I have the Gemini plan, and then I have OpenAI's plan... And I use the agents and I say, 'You go out and find me every state entity... that has an open records opportunity.'" 00:17:34

agentfeeds.dev

Cuban's experimental project for feeding creator content/ads to agents. Cuban: "it's called agentfeeds.dev, and the whole idea is you take the transcript of your posts... and you copy and paste it into their agents." 00:30:43

UnitedHealth, CVS, Cigna (the "BUKAs")

Referenced as vertically integrated incumbents (the villains in Cuban's analysis). Cuban: "UnitedHealth, 3,000-plus subsidiaries, $150 billion in intercompany transfers annually." 00:00:15

Stat News

Mentioned as having just covered the pod N-of-1 manufacturing story. Cuban: "actually Stat News just wrote a story on this yesterday or the day before." 00:04:18

4. People Identified

Mark Cuban

Entrepreneur, Dallas Mavericks owner, co-founder of Cost Plus Drugs. Julie Yoo credits his courage and platform: "Mark first of all just had the courage to enter into the morass that is healthcare in a way that made such a splash and that many, many people who also are in the privileged position that Mark is in... have been intimidated to do over many, many decades." 00:02:11

Dr. Alex Oshmyansky

Co-founder of Cost Plus Drugs, driving the manufacturing vision. Cuban: "Alex, my co-founder, Dr. Alex Oshmyansky, his original cold email to me was he wanted to manufacture drugs that were generic drugs that are on the FDA short supply list." 00:04:18

a16z general partner (Bio + Health) who published a piece on the "great replacement cycle" of health plans. Cuban builds on her framing: "you brought up the point right at the beginning, Julie, and you're 100% right. We are not in an efficient healthcare market." 00:14:34

Erik Torenberg

Host who raised the Aaron Swartz framing and the national policy question. Torenberg: "if you were president or if you were advising the next president... what is the leverage to most address our health care challenges." 00:48:39

Aaron Swartz

Referenced for "information wants to be free," the premise Cuban challenges. Torenberg: "there's this famous Aaron Swartz quote from many years ago, 'You know information wants to be free.'" 00:36:45

Luka Dončić

Referenced as the namesake of a $77.69 Grok plan Cuban uses. Cuban: "I got the Luka Dončić plan cuz it's $77.69 or something." 00:17:34

Ken Paxton and James Talarico

Texas political figures, mentioned to illustrate algorithmic information silos. Cuban: "their friends didn't even know, living in Texas, didn't even know who Ken Paxton or James Talarico were." 00:53:13

5. Operating Insights

Hire a Single Owner for Healthcare Contracts

Cuban's prescription for employers is organizational: dedicate a role whose only job is benefits contract management. Cuban: "bring in somebody that I call a healthcare CEO or CFO whose only job is to manage the contracts and everything associated with it, and you will find that your healthcare costs will go down." 00:17:34

Use Multiple Models in Adversarial Review

Cuban cross-checks LLM outputs by feeding one model's conclusions to another and having them debate. Cuban: "I start with one and said, 'Hey, one of your peers came out and said this about this contract, what do you think?' and spend a couple hours." 00:57:25 Also: "I've held phones up next to each other and take the output and had them to have a conversation with each other so I could listen in." 00:57:25

Automate the Backlog You Never Had Time For

Cuban uses agents to draft open-records requests, then watches a shared drive for new data and triages it. Cuban: "Stuff that's always been at the bottom of the list that I always wanted to get to, but never could. Now it's just like this stuff is coming... every time there's a new something new loads on the drive, you go through, you tell me... the good news, you give me the bad news, you give me what should be done, and then you give me the simple version." 00:17:34

Give Execs Hands-On AI Demos Tied to Their Own Product

The cookie example is a repeatable sales and education tactic: take the client's flagship product and have an LLM design its disruptor live. Cuban: "let's take your number one product, your cookie... I'm going to ask ChatGPT to create a competitor that is more GLP-1 friendly and will be priced lower." 00:27:48

Keep Hiring Entry-Level, Because Models Lag

Cuban argues against eliminating junior roles. Cuban: "You have to still hire entry-level people. Because no matter what the model is, the minute it's released, that's it, right? It's behind... there's latency associated with every model." 00:27:43 And: "AI doesn't replace jobs, people who know how to use AI replace the jobs of people who don't know how to use AI." 00:27:48

6. Overlooked Insights

The Hospital Financial-Assistance Wedge Is an Unbuilt Business

Cuban casually outlines a startup idea: getting nonprofit hospitals to publish agent-readable financial assistance information that consumers' personal AIs can query. He notes eligibility can go up to 600% of the federal poverty level (over $100,000 for some families). Cuban: "If I was going to start a company um, in this space, I would go to every nonprofit hospital and set up a plan that post agents that I enable people to use... copy and paste this into your Muse or into your Dot or into, you know, your Claude Cowork, whatever it is, and it'll know to come here to us and ask questions." 00:30:43 The implication is that hospitals are dependent on carrier networks for patient flow, and an agent-addressable direct-to-patient channel could break that dependency: "You are dependent on the BUCAs and their plans and being part of their network to feed you patients. That's ridiculous, right?" 00:34:45

The ANDA Filing Fee Is the Real Bottleneck on Onshoring Generics

Mentioned almost in passing, the gating factor on domestic AI-driven generic manufacturing is regulatory cost per drug, not technology: roughly $365,000 each. Cuban: "each one of those things cost $365,000 plus other fees. So, you want to do a 1,000 of them, that's $365 million plus all the cost of the pods... if we truly want to bring manufacturing and onshore it for medications, we're here for it, and we can do it." 00:23:20 This points to a policy or philanthropic or public-private financing opportunity (subsidizing ANDA costs) with outsized leverage on supply-chain resilience.